Member Info for Laura2022

Breakout ?

Ýeah Truro

Another really impressive overview by Peter

Yes ..Goldman reduced by 1% and Norges by 2% but Redwood by 4 %

Maybe they took the shares from tje other 2

Strategy seminar

On 27 March 2024, the Group will set out its strategy to deliver an adjusted return on tangible equity2 (ROTE) in the mid-teens from 2026. This significant improvement will be driven by a return to sustainable income growth, together with the benefits of greater efficiency. At its strategy seminar, the Group will describe in detail the initiatives already under way to serve a broader, carefully targeted addressable market with a more extensive customer proposition. It will also present a detailed route map to achieve significant payback across the business in 2026 from its technology infrastructure investment.

 

Apologies

2/3

All 3 small trades were buys too yesterday

But still no comment on CPX which you ramped all week

You're like an ambulance chaser on every share apart from your own

Because at the time it was made (and reporting delayed) it was 1.21 sell and 1.27p buy

Ilovesushi

Posted in: CPX

Posts: 3,383

Price: 0.275

No Opinion

POSSIBLE TAKE-OVER COMINGToday 12:20

Dr Graham Cooley could now have approximately 25% holding depending on his buying the last tranche of Conaccording holding add taking the shares from Quilter.

He could then announce a take-over deal. Or at the very least a short term loan with a board position.

0.5 pence price target.

Went missing in Dec now gone missing again

Yet preaches on other boards

Will try to confirm via a link....apparently its on Adfvn but has been removed.. I don't know how to access that site?

Rumours of private capital bid for VANQ

This month the Physiomics team attended the 14th Annual World ADC Event in London on 13th and 14th of March 2024, Europe’s definitive Antibody-Drug Conjugate meeting, attended by 600+ experts from the field. It was a great event to meet with leaders of the field and learn about the trends and lessons in this exciting and growing industry. In particular to discuss where quantitative pharmacology and PK/PD modelling expertise can help to inform and de-risk development, in areas such as;

Discovery:

Model impact of ADC design, including properties such as binding affinity to target, payload release rate, elimination rate, half-life, DAR etc. on payload delivery to the tumour, to inform selection of your lead candidate

Pre-clinical/Translation:

Predict human PK & PD to select FIH dose and understand optimal dose range in the clinic

Clinical development;

Understand exposure-response relationships in both safety and efficacy for all components of the ADC (total antibody, ADC, free payload)

Alter dosing schedule to reduce toxicity

Define dosing strategies for specific patient populations or sub-groups

For more information on the clinical pharmacology considerations for development of ADC’s, see the Guidance for Industry issued by the FDA’s Center for Drug Evaluation and Research or discuss with the team at Physiomics!

Largest buy for a while

Great Post Ant

To my knowledge I've never seen Bayer officially mentioned

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK

Thanks Trench....very recent as written 18th March

With the US government’s unveiling of the Precision Medicine Initiative in 2015 and investing $215 million in the National Institutes of Health (NIH)’s 2016 budget—with an additional $54 million announced in 2023—precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.

Just like CPX which you were pumping in December which then lost 95% amd you went silent

Record 1st half revenues ever

Losses down and breakeven due

Pipeline up 50% to £1.5mln

The Directors are pleased that the Company is on track to meet expectations, which, if achieved, would mean a significant increase in total income compared with the financial year ended 30 June 2023.

Ilovesushi

You went silent on CPX at 2p in Decemeber

You then returned to CPX last week after a 95% fall

Cpx has lost money for 20yrs

Buzz off